COVID-19 vaccine – Long term immune decline and breakthrough infections

BACKGROUND: Since the introduction of BNT162b2 mRNA COVID-19 vaccine by Pfizer in late 2020, efficacy and immunogenicity waning of COVID-19 vaccines was reported, and decision making regarding a booster remains a top priority worldwide, a decision that should be made based on breakthrough infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoury, Johad, Najjar-Debbiny, Ronza, Hanna, Ayman, Jabbour, Adel, Abu Ahmad, Yara, Saffuri, Amer, Abu-Sinni, Majdole, Shkeiri, Rashed, Elemy, Ameer, Hakim, Fahed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556595/
https://www.ncbi.nlm.nih.gov/pubmed/34763949
http://dx.doi.org/10.1016/j.vaccine.2021.10.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556595/
https://www.ncbi.nlm.nih.gov/pubmed/34763949
http://dx.doi.org/10.1016/j.vaccine.2021.10.038

Ejemplares similares